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ABSTRACT
Introduction: In this literature review we
evaluated the real-world clinical effectiveness
of switching Japanese diabetic patients from
their current insulin regimen to insulin
degludec (IDeg).
Methods: Studies were identified from Japanese
Diabetes Society (JDS) abstracts (2014–2015)
and PubMed (2012 onwards). Inclusion criteria
were: Japanese population, [15 participants,
and studies switching patients from basal or
basal–bolus insulin regimens to IDeg.
Randomized controlled trials and case reports
were excluded. Weighted mean changes in
safety and effectiveness endpoints were
calculated using the number of patients in
each study.
Results: In total, 81 JDS abstracts and seven
manuscripts met the search criteria,
representing 4238 patients [1028 with type 1
diabetes (T1D), 602 with type 2 diabetes (T2D),
2608 with unspecified or mixed diabetes].
Glycated hemoglobin (HbA1c) was reported in
93% of studies, with an improvement in 84% of
these (51% significant, 33% numerical), no
change in 12%, and worsening in 4% (3%
numerical, 1% significant). Across all studies,
the weighted mean absolute change in HbA1c
was -0.3% (-2.7 mmol/mol). Basal insulin dose
was reported in 58% of studies and was lower in
60% of these (30% significant, 30% numerical),
numerically unchanged in 26%, and higher in
14% (2% significant, 12% numerical). The
weighted mean change in basal insulin dose
was -4.8% and -3.0% for all studies and for
studies with only significant results,
respectively. The weighted mean change in
basal dose based on all studies was -8.9, -5.5,
and -2.9% for the T1D, T2D, and unspecified
patient populations, respectively.
Hypoglycemia was recorded in 31% of the
studies. After switching treatment to IDeg,
55% of studies reported decreased
hypoglycemia, 29% no change, and 16% an
increase. Quality of life (QoL) was measured in
11% of studies, of which 82% reported
improved QoL after switching, and 18%
reported no change in QoL.
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INTRODUCTION
Randomized controlled trials (RCTs) are the
gold standard for comparing the safety and
efficacy of new therapeutic agents against
current practice; however, their external
validity is limited by the study design, and
inclusion and exclusion criteria [1]. For ethical,
regulatory, and scientific reasons, the
populations enrolled in phase 3 clinical trials
differ from those of real clinical practice in
terms of their clinical characteristics.
Standardization of trial populations is
required to reduce confounding and to allow
statistical comparisons to be made regarding
the safety and efficacy of the therapies being
evaluated. Many clinical trials also include a
run-in period, which further reduces
heterogeneity [2]. As a result of these
differences, there is a divergence between the
narrowly defined patient profiles of RCTs and
real-world prescribing decisions, leaving a
knowledge gap between the evidence base of
phase 3 trials and clinical practice.
Results from phase 3 trials have shown that
insulin degludec provides a range of clinical
benefits, including a reduction in insulin dose
requirements, a lower risk of hypoglycemia, and
improvements in quality of life (QoL),
compared with conventional long-acting basal
insulins [3–9]. The insulin degludec phase 3
trials used a treat-to-target methodology, as
recommended by the European Medicines
Agency [10] and U.S. Food and Drug
Administration [11]. Treat-to-target trials with
insulin evaluate both the benefits of glycemic
control and the associated side effects, such as
hypoglycemia, which allow risk–benefit
assessments to be made. In treat-to-target
studies, the insulin dose is adjusted for each
individual patient, the aim of which is to
achieve identical glycemic targets for both
treatment arms. The main difference between
insulin therapies evaluated using this
methodology is observed in safety parameters
(e.g., rates of hypoglycemia). In all of the phase
3 trials versus insulin glargine U100 carried out
to date, insulin degludec resulted in
non-inferior reductions in glycated
hemoglobin (HbA1c) [12–20].
Assessing the clinical effectiveness of insulin
degludec in a real-world population could help
to inform the decisions of healthcare
practitioners and improve diabetes
management by complementing data from the
phase 3 program. Japan was one of the first
countries in which insulin degludec was
launched, and there is a growing body of
literature reporting real-world clinical
outcomes [21–24].
The aim of this literature review was to
evaluate the real-world clinical effectiveness of
switching Japanese diabetic patients to insulin
degludec therapy.
METHODS
A literature search was conducted using the
MEDLINE, I-Dis, and JDreamIII (2012 onwards)
databases, and Japanese Diabetes Society (JDS)
abstracts (2014–2015). Only studies in Japanese
populations were included; however, searches
included publications written in either the
Japanese or English language. Japanese
language publications were translated into
English for the purpose of this review.
Inclusion criteria were a minimum of 15
patients in each study, and only those studies
in which patients switched from a conventional
insulin regimen to insulin degludec (i.e., no
insulin-naı¨ve patients). RCTs and case reports
were excluded. Two independent researchers
assessed the abstracts for inclusion/exclusion
criteria. The primary measures of clinical
effectiveness were HbA1c level, total daily basal
insulin dose, and hypoglycemia. QoL was
reported as a secondary measure of clinical
effectiveness.
190 Diabetes Ther (2017) 8:189–195
Changes in endpoints were classified as
either an improvement (reduction in HbA1c,
basal insulin dose, or incidence of
hypoglycemia; or an increase in QoL),
unchanged, or worsening (increase in HbA1c,
basal insulin dose or incidence of
hypoglycemia; or a decrease in QoL). When
numerical changes were reported, results were
stratified into two groups: (1) studies with
significant changes only, and (2) all studies
irrespective of significance. Using the sum of
patients in each abstract, patient-weighted
changes were calculated for studies in which
only significant changes were observed, and for
all studies irrespective of significance. That is, if
a study reported a numerical but insignificant
change in an endpoint, the patients in that
study would be included in the significant
patient-weighted calculation as patients with
no change in the endpoint. In the alternative
patient-weighted calculation, these patients
would be included as per the numeric change.
Stratification of data by diabetes type was
carried out where there were a sufficient
number of observations to justify it. Results
were reported as percentages for the numbers of
studies reporting improvement, no change, or
worsening in endpoints and as mean absolute
percentage change and relative percentage
change for HbA1c and insulin dose, respectively.
This review is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
RESULTS
A total of 81 JDS abstracts and seven
manuscripts met the search criteria [21
involving type 1 diabetes (T1D) patients, 17
involving type 2 diabetes (T2D) patients, and 50
involving patients whose diabetes type was not
specified or was mixed], representing 4238
patients (T1D 1028, T2D 602, not specified
2608; Table 1 and Electronic Supplementary
Material Tables S1–S3, Fig. S1).
HbA1c was reported in 93% of studies
(n = 3873 patients), of which an improvement
in HbA1c was observed in 84% (51% significant
change, 33% numerical but not significant), no
change was observed in 12% of studies, and a
worsening of HbA1c was observed in 4% (1%
significant, 3% numerical; Fig. 1). Across all
studies, the patient-weighted mean absolute
change in HbA1c was -0.3% (-2.7 mmol/mol)
(Table 1).
Basal insulin dose was reported in 58% of
studies (n = 2573 patients) and was lower
(improved) in 60% of these (30% significant,
30% numerical), numerically unchanged in
26%, and higher in 14% (2% significant, 12%
numerical; Fig. 1).
The weighted mean relative change in basal
insulin dose was -4.8% and -3.0% for all
studies and for studies with only significant
results, respectively (Table 1). The weighted
Table 1 Participant characteristics and clinical outcomes




Total study population, n 4238
Diabetes type, n (%)
T1D 1028 (24%)
T2D 602 (14%)
Not speciﬁed 2608 (62%)
Change in HbA1c, % (mmol/mol)
Weighted mean absolute change
from baseline in HbA1c
–0.3%
(-2.7 mmol/mol)
Change in basal insulin dose, %
Weighted mean relative change
from baseline in basal insulin
dose (all studies)
-4.8%
Weighted mean relative change
from baseline in basal insulin
dose (only studies reporting a
signiﬁcant change)
-3.0%
Age, duration of diabetes, gender, hypoglycemia rates and
quality-of-life scores were not listed by all abstracts and are
therefore not included in the table
HbA1c Glycated hemoglobin, T1D type 1 diabetes, T2D
type 2 diabetes
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mean relative change in basal dose for all
studies stratified by diabetes type was -8.9,
-5.5, and -2.9% for T1D, T2D, and unspecified
populations, respectively.
Hypoglycemia was recorded in 31% of the
studies (n = 1414 patients). After the patient
had been switched to insulin degludec therapy,
55% of these studies reported decreased
hypoglycemia, 29% reported no change, and
16% reported an increase (Fig. 1).
QoL was measured in 11% of studies (n = 747
patients), of which 82% reported improved QoL
after the switch to insulin degludec and 18%
reported no change in QoL (Fig. 1).
DISCUSSION
This literature review reports the clinical impact
of switching to insulin degludec from
conventional basal or basal–bolus regimens in
real-world Japanese populations. The collated
evidence from clinical practice demonstrates
that switching to insulin degludec is associated
with improved glycemic control, a reduction in
patients’ basal insulin dose requirement, and a
lower risk of hypoglycemia. Insulin degludec is
also associated with an improvement in QoL.
The findings of this review concur with those
of clinical trials in which similar improvements
in clinical efficacy and patient-reported
outcomes have been observed [3–7, 9]. In
comparison with real-world studies, a recently
published small-scale (n = 51), retrospective,
single-center investigation reported similar
improvements in HbA1c after switching to
insulin degludec, with reductions of 0.5 and
0.7% in patients with T1D and T2D,
respectively [25]. In the same study, there was
a significant [90% reduction in the rate of
hypoglycemia despite an increase in insulin
dose. However, it should be noted that one of
the inclusion criteria for switching to insulin
degludec was the experience of recurrent
hypoglycemia [25]. Another real-world study
in patients with T1D (n = 357) reported that
after the switch to insulin degludec, patients’
HbA1c improved by 0.3% while the insulin dose
was reduced by 12%. The switch to insulin
degludec was also associated with a 20%
reduction in the rate of overall hypoglycemia
and a halving of the rate of nocturnal
hypoglycemia [26].
The reasons for the reduction in insulin dose
in the patients included in the present study are
unclear, but they could be related to the
long-acting and predictable pharmacodynamic
profile of insulin degludec [27]. Further studies
are needed to explore the relationship between
insulin degludec and bolus insulin dose
requirements, but there is evidence from both
clinical practice and clinical trials
demonstrating a reduction in total daily
insulin requirements in patients treated with
insulin degludec [28, 29]. A lower risk of
hypoglycemia together with lower HbA1c
appears to be counter-intuitive; however, the
reduced variability in blood glucose
concentrations exhibited by insulin degludec,
compared with insulin glargine U100, could be
responsible for this observation [30]. The
improvements in clinical outcomes and QoL
may be associated. For example, reducing the
incidence of nocturnal hypoglycemia might
improve patients’ general sense of well-being.
Alternatively, the potential for flexible dose
timing or the FlexTouch pen device (Novo
Nordisk, Bagsværd, Denmark) used for the
delivery of insulin degludec could also have a
positive effect on QoL. Notably, there were no
reports of worsening in QoL. It is also possible
that the clinical benefits observed in our review
are the result of patients switching to a new
Fig. 1 Safety and effectiveness of insulin therapy in the
reviewed studies. The percentage of studies reporting an
improvement, no change, or deterioration (irrespective of
signiﬁcance) are shown. Percentages were calculated using
the number of patients in all studies reporting each
endpoint. HbA1c Glycated hemoglobin
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basal insulin and receiving closer clinical
support or being motivated to adhere more
strictly to their injection schedule and titration
algorithm, rather than a direct pharmacological
effect, but this should not be dismissed as
insulin degludec provides an additional
treatment option for clinicians. This study’s
findings may help to inform the decisions of
both medical practitioners and healthcare
payers in terms of considering treatment
options for patients failing to reach blood
glucose targets on conventional basal or
basal–bolus insulin regimens.
This review is subject to limitations. Foremost,
there is a possibility of overlap between the
populations in the different abstracts. The
decision to limit abstract selection to the largest
Japanese diabetes congress (JDS) should have
helped to reduce this risk as multiple
submissions on the same study are discouraged.
There is a greater possibility of overlap between
the abstract and manuscript populations, but as
the number of manuscripts included in the review
was small, this should not have had a large effect
on the observations. Furthermore, there is no
suggestion that where overlap hypothetically
exists, it would affect the direction of the results.
Other limitations include the lack of a consistent
definition for hypoglycemia across all studies and
the absence of significance/non-significance
being reported for the change in endpoints in
some studies. The heterogeneity of populations
included in the present analysis could introduce
confounding or bias, which might influence the
magnitude of reported outcomes. This is an
inherent part of all real-world analyses, which
sets them apart from highly controlled clinical
trials. These limitations have an impact on the
generalizability of the results. Large-scale
observational studies, with greater uniformity in
the recording of population characteristics and
outcomes, are required to confirm the findings of
our analysis.
CONCLUSION
Real-world evidence from Japanese clinical
practice demonstrates that switching to insulin
degludec has the potential to improve glycemic
control and reduce insulin dose requirements.
Switching to insulin degludec may also provide a
reduced risk of hypoglycemia and the potential
for improvement in QoL.
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